Sintilimab  (Synonyms: IBI308)

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer^{[1][2][3][4][5]}.

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Sintilimab (12 h) shows a high level of PD-1 occupancy and has superior T cell activating characteristics in human peripheral blood mononuclear cells (PBMCs)^[2].
Sintilimab (0.16-100 nM; 5 days) induces high secretion levels of IFN-γ and IL-2 in primary T cell assays^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sintilimab (0.1 mg/kg, 1 mg/kg and 10 mg/kg, i.p., a single dose for 1, 8, 12, 15 days) shows antitumor effects against NCI-H292 tumors in a humanized mouse model^[2].
Sintilimab (1 mg/kg, 3 mg/kg and 10 mg/kg, s.c., a single dose) demonstrates a high affinity for PD-1 molecules in NCI-H292 tumor-bearing NOG mice^[2].
Sintilimab (20 mg/kg, i.p., once interval 2 days for 21 days) combined with prebiotics inhibits the volume of transplanted tumors in lung adenocarcinoma and alleviates the liver and kidney injury^[4].

Pharmacokinetic parameters of Sintilimab (10 mg/kg, i.v., a single dose) in hPD-1 knock-in mouse^[2]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.04 kDa

2072873-06-2

Liquid

Colorless to light yellow

[Sintilimab]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) can bind Sintilimab. The EC₅₀ for this effect is 6.653 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) labeling Sintilimab (HY-P99048, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346.  [Content Brief]

  [2]. Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11(8):1443-1451.  [Content Brief]

  [3]. Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558.  [Content Brief]

  [4]. Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23(17):1966-1973.  [Content Brief]

  [5]. Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10(1):23.  [Content Brief]

  [6]. Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955.  [Content Brief]